MA5-12663

antibody from Invitrogen Antibodies

Targeting: KRT19 CK19, K19, K1CS, MGC15366

Provider product page for MA5-12663

Western blot

Antibody data

Antibody Data
Antigen structure
References [53]
Comments [0]
Validations
Western blot [3]
Immunocytochemistry [1]
Immunohistochemistry [1]
Flow cytometry [1]
Other assay [11]

Submit

Product number: MA5-12663 - Provider product page
Provider: Invitrogen Antibodies
Product name: Cytokeratin 19 Monoclonal Antibody (A53-B/A2.26 (Ks19.1))
Antibody type: Monoclonal
Antigen: Other
Description: MA5-12663 targets Cytokeratin 19 in IF, IHC (P), and WB applications and shows reactivity with Human samples. The MA5-12663 immunogen is human breast cancer MCF-7 cells.
Reactivity: Human
Host: Mouse
Isotype: IgG
Antibody clone number: A53-B/A2.26 (Ks19.1)
Vial size: 500 µL
Concentration: 0.2 mg/mL
Storage: 4° C

KRT19 protein structure - MA5-12663 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot of Cytokeratin 19 using Cytokeratin 19 Monoclonal Antibody (Product # MA5-12663) on LS174T Cells.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis was performed on whole cell extracts of MCF7 (Lane 1), T-47D (Lane 2), Hep G2 (Lane 3), HT-29 (Lane 4). The blots were probed with Anti-Cytokeratin 19 Mouse Monoclonal Antibody (Product # MA5-12663, 2 µg/mL) and detected by chemiluminescence using Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, HRP conjugate (Product # A28177, 0.4 µg/mL, 1:2500 dilution). A ~ 44 kDa band corresponding to Cytokeratin 19 was observed across cell lines tested. The second band observed may correspond to another Cytokeratin. Known quantity of protein samples were electrophoresed using Novex® NuPAGE® 4-12 % Bis-Tris gel (Product # NP0321BOX), XCell SureLock™ Electrophoresis System (Product # EI0002) and Novex® Sharp Pre-Stained Protein Standard (Product # LC5800). Resolved proteins were then transferred onto a nitrocellulose membrane with iBlot® 2 Dry Blotting System (Product # IB21001). The membrane was probed with the relevant primary and secondary Antibody following blocking with 5 % skimmed milk. Chemiluminescent detection was performed using Pierce™ ECL Western Blotting Substrate (Product # 32106).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis was performed on whole cell extracts of MCF7 (Lane 1), T-47D (Lane 2), Hep G2 (Lane 3), HT-29 (Lane 4). The blots were probed with Anti-Cytokeratin 19 Mouse Monoclonal Antibody (Product # MA5-12663, 2 µg/mL) and detected by chemiluminescence using Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, HRP conjugate (Product # A28177, 0.4 µg/mL, 1:2500 dilution). A ~ 44 kDa band corresponding to Cytokeratin 19 was observed across cell lines tested. The second band observed may correspond to another Cytokeratin. Known quantity of protein samples were electrophoresed using Novex® NuPAGE® 4-12 % Bis-Tris gel (Product # NP0321BOX), XCell SureLock™ Electrophoresis System (Product # EI0002) and Novex® Sharp Pre-Stained Protein Standard (Product # LC5800). Resolved proteins were then transferred onto a nitrocellulose membrane with iBlot® 2 Dry Blotting System (Product # IB21001). The membrane was probed with the relevant primary and secondary Antibody following blocking with 5 % skimmed milk. Chemiluminescent detection was performed using Pierce™ ECL Western Blotting Substrate (Product # 32106).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 8 The effect of MMP-9 downregulation on Cytokeratin 19 (CK19) level. NT--non-transfected cells, T--cells transfected with MMP-9 siRNA, NT5 and T5 non-transfected and transfected cells treated with 5 mM cyclophosphamide for 24 h. ( A ) Immunofluorescent imaging of Cytokeratin 19 (red), and nuclei (blue), and cytometric relative fluorescence intensity of Cytokeratin 19, Bar = 50 mum. ( B ) The Western blot analysis of Cytokeratin 19 and densitometric relative measurement of the Western blot experiments. Statistically significant differences were marked with '*' p

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 7 Cytokeratin (CK)-19, CK-14 and vimentin triple immunofluorescence staining. High mammographic density (HMD) ( a ) and low mammographic density (LMD) ( b ) tissue samples were stained with 4',6-diamidino-2-phenylindole ( a 1 and b 1 ), CK-14 ( a 2 and b 2 ) CK-19 ( a 3 and b 3 ) and vimentin ( a 4 and b 4 ) and assessed as composite images ( a 5 and b 5 ). Arrows indicate cells inside the epithelial layer that stained negative for CK-19 or CK-14, but positive for vimentin. ( c ) Using the point-counting method, the percentages of CK-14 basal epithelial cells and CK-19 luminal epithelial cells were determined, as were the number of vimentin-expressing CK - cells per whole glandular area of the tissue sections. The results for HMD and LMD paired samples were analysed using the nonparametric Wilcoxon matched-pairs signed-rank test. VPCKN vimentin-positive, cytokeratin-negative. Scale bar = 10 mum

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 2 Characterization of pancreatic ductal epithelial cells. ( a - f , l : Characterization of organoids). a Characterization of pancreatic ductal organoids using epithelial cell markers, b cytokeratin 19 (KRT 19, c E-cadherin, e sodium transport channel (ENaC), and f ZO-1. d Hematoxylin and eosin (H&E) image shows the orientation of pancreatic ductal epithelial cells in spheroid of the organoid. ( g - k : Characterization of monolayer of pancreatic ductal epithelial cells (PDECs)). g Phase contrast and j H&E images show monolayer of PDECs formed from the organoids. Monolayer of PDECs showed positivity for tight junction h ZO-1, i F-actin and KRT 19, and k cystic fibrosis transmembrane conductance regulator (CFTR). l RNA-sequencing data was obtained from the pancreatic ductal organoids and verified the PDEC origin ( n = 4 sample preparation from the same patient). Data are mean +- SD. Scale bars: 10 um ( k ), 20 um ( b , c , e , f , h - j enlarge), 50 um ( d , g , j ), and 500 um ( a )

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: IHC pictures of serial paraffin-embedded sections of tumours and ALN metastases stained with antibodies against CK15 (monoclonal) and CK19. Black arrows in (A) and (B) indicate cells that express both CK15 and CK19. Red arrows in (C) and (D) indicate cells that express only CK15, while blue arrows indicate cells that express only CK19.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: IHC staining of serial paraffin-embedded sections of tumour 71 stained with antibodies against (A) CK15 (monoclonal) and (B) CK19. Areas with cells exhibiting different CK15/CK19 phenotypes are indicated for reference. A region containing apocrine cells as judged by the distinct morphological features of these lesions is indicated within a box. The heterogeneity of the tumour in terms of CK15/CK19 phenotypes is clearly illustrated in these sections.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Phenotype of non-malignant CK15+/CK19+ cells present in tumour 71. Panel A. Serial sections of paraffin-embedded tissue stained with antibodies against (A) CK15 (monoclonal), (B) CK19, (C) CK7, (D) CK8 (the black arrows indicate strongly positive cells), (E) (PgR), (F) CK14 and (G) vimentin. Only the area boxed in (A) is shown at larger magnification in figures B-G. The red arrows in G indicate vimentin negative cells. The phenotype of the cells is given at the top of Panel A. Panel B. Another area of the same section reacted with antibodies against CK15 (H), CK19 (I), CD44 (J), and GATA-3 (H). Blue arrows indicate CK15+/CK19+ cells, while the red arrows indicate CK15-/CK19+ cells which are differentiated as judged by the expression of GATA-3 (K).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: IHC of non-malignant and premalignant lesions present in tumour 71. Panel A. Area with HUT 1 contiguous to CK15+/CK19+ cells stained with antibodies against CK15 (monoclonal) (A), CK19 (B), vimentin (C) and p53 (D). Panel B. ADH 1 contiguous to CK15+/CK19+ columnar cells reacted with antibodies against CK15 (E), CK19 (F), and p53 (G) (Table 2). For reference, (H) shows the invasive part of the tumour reacted with p53. Panel C. Ductal carcinoma in situ from T71 reacted with antibodies against CK15 (I), CD44 (J), vimentin (K), Bcl-2 (L), and psoriasin (S100 A7) (M). The red arrow in (K) indicates vimentin positive cells, while the blue one indicates negative ones.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: CK15+ cells in normal TDLUs. Serial sections of normal ducts and lobules from biopsies of patients 14 (A, B) and 54 (C, D) stained with the CK15 (monoclonal) (A, C) and CK19 antibodies (B, D), respectively. Red arrows in (A) and (B) indicate cells that express either CK15 or CK19. Blue arrows in (C) and (D) indicate cells that co-express CK15 and CK19.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: CK15+/CK19+/CK14+ progenitor 1 cells in human large collecting ducts of the breast. Panel A. Serial sections of collecting ducts from patient 27 stained with antibodies against CK15 (polyclonal, Aviva) (A), CK19 (B), CK8 (C), PgR (D), CK14 (E) and GATA-3 (F). The phenotype of the progenitor cells (black arrows) in given for reference. The red arrow in (C) indicates a CK8 positive cell. Panel B. CK8 positive cells present in a large collecting duct of patient 27 with epithelial hyperplasia. Serial of collecting ducts were stained with antibodies against CK8 (G), CK15 (H), AR (I), and GATA-3 (J). The phenotype of the CK8 positive cells indicated with a black arrow is given for reference.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: CK15+/CK19+ cells present in the ducts of a juvenile fibroadenoma with epithelial hyperplasia. Panel A. Serial sections stained with the CK15 (polyclonal Aviva) (A) and CK8 antibodies (B) respectively. Red arrows indicate areas of the duct with CK15 positive cells, while blue ones indicated CK8 positive cells. Panel B. Serial sections of another area of the juvenile fibroadenoma stained with antibodies against CK19 (C), PgR (D), and Bcl-2 (E). Red arrows indicate areas of the duct with CK15+/CK8- cells, while blue ones indicate CK8+/CK15- cells. The extended phenotype of both cell types are given for reference.